In 2024, prostate cancer (PCa) remains the most common non-skin cancer in males within the ... Outcomes are not good for patients who harbor these aggressive phenotypes alongside favorable ...

In NCCN favorable intermediate-risk (FIR) prostate cancer (PCa) patients treated with radical prostatectomy (RP), we tested the effect of upstaging and upgrading on cancer-specific mortality (CSM).

Do you consider the cancer measurements to be small, thus making the “observation only” protocol correct? — B.A. Dear B.A.: ...

Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer is the most prevalent cancer among men ... testing while the National Comprehensive Cancer Network supports their use in initial ...

If you do have prostate cancer that is confined to the organ, your five-year survival rate is nearly 100%. Evidence shows favorable outcomes when men diagnosed with low-risk or some intermediate ...

Eligible participants were men with newly diagnosed low-risk or low-volume, favorable intermediate-risk prostate cancer who were eligible for active surveillance. Data were analyzed from January 2015 ...

Prostate cancer kills 35,000 men a year, according to Dr. Roach. But not all cancers are treated the same way.

I am a 66-year-old white male who is active and relatively healthy. I have recently been diagnosed with prostate cancer. One ...